-

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) held on May 21, 2025. Detailed results of the vote follow:

Name

For

 

Against

 

Broker Non-Votes

Nathalie Bernier

 

337,617,248

 

1,924,336

 

8,383,437

Gary Hu

 

337,591,706

 

1,949,878

 

8,383,437

Brett Icahn

 

337,474,287

 

2,067,297

 

8,383,437

Sarah B. Kavanagh

 

337,602,211

 

1,939,373

 

8,383,437

Karen L. Ling

 

337,526,114

 

2,015,470

 

8,383,437

John A. Paulson

 

337,650,735

 

1,890,849

 

8,383,437

Russel C. Robertson

 

337,600,880

 

1,940,704

 

8,383,437

Thomas W. Ross, Sr.

 

337,583,018

 

1,958,566

 

8,383,437

Brenton L. Saunders

 

337,592,062

 

1,949,522

 

8,383,437

Andrew C. von Eschenbach, M.D.

 

337,607,276

 

1,934,308

 

8,383,437

Shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor’s remuneration.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

More News From Bausch + Lomb Corporation

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously...

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting...

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p...
Back to Newsroom